Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database

PURPOSE: Eculizumab, a drug that blocks activation of the terminal complement pathway, is useful in the treatment of several rare diseases. However, eculizumab-related meningococcal disease is a serious problem. Because of the difficulty diagnosing meningococcal disease, deaths from meningococcal di...

Descripción completa

Detalles Bibliográficos
Autor principal: Matsumura, Yumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666998/
https://www.ncbi.nlm.nih.gov/pubmed/33204170
http://dx.doi.org/10.2147/DHPS.S257009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666998/
https://www.ncbi.nlm.nih.gov/pubmed/33204170
http://dx.doi.org/10.2147/DHPS.S257009

Ejemplares similares